These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 2680241

  • 21. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H, Mimura T, Honda N.
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Erythropoietin therapy in patients with chronic renal failure.
    Pinevich AJ, Petersen J.
    West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
    [Abstract] [Full Text] [Related]

  • 26. [Treatment of anemia in patients with chronic renal insufficiency with recombinant human erythropoietin].
    Djukanović Lj, Lezaić V.
    Srp Arh Celok Lek; 1996 Aug; 124(3-4):93-7. PubMed ID: 9102827
    [Abstract] [Full Text] [Related]

  • 27. Safety and tolerability of a multidose formulation of epoetin beta in dialysis patients. Collaborative Study Group.
    Raftery MJ, Auinger M, Hertlová M.
    Clin Nephrol; 2000 Sep; 54(3):240-5. PubMed ID: 11020023
    [Abstract] [Full Text] [Related]

  • 28. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U.
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [Abstract] [Full Text] [Related]

  • 30. Clinical characteristics of erythropoietin-associated pure red cell aplasia.
    Carson KR, Evens AM, Bennett CL, Luminari S.
    Best Pract Res Clin Haematol; 2005 Dec; 18(3):467-72. PubMed ID: 15792921
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Management of blood pressure changes during recombinant human erythropoietin therapy.
    Levin N.
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):16-20. PubMed ID: 2669081
    [Abstract] [Full Text] [Related]

  • 33. Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis.
    Zehnder C, Blumberg A.
    Clin Nephrol; 1989 Feb; 31(2):55-9. PubMed ID: 2920469
    [Abstract] [Full Text] [Related]

  • 34. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
    Gejyo F, Saito A, Akizawa T, Akiba T, Sakai T, Suzuki M, Nishi S, Tsubakihara Y, Hirakata H, Bessho M, Japanese Society for Dialysis Therapy.
    Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
    [Abstract] [Full Text] [Related]

  • 35. [Chemical structure, biotechnical production and clinical use of recombinant erythropoietin].
    Fandrey JK, Jelkmann WE.
    Z Gesamte Inn Med; 1992 Jun; 47(6):231-8. PubMed ID: 1642021
    [Abstract] [Full Text] [Related]

  • 36. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B, Grujić-Adanja G.
    Srp Arh Celok Lek; 1997 Jun; 125(5-6):163-7. PubMed ID: 9265238
    [Abstract] [Full Text] [Related]

  • 37. Recombinant human erythropoietin therapy in the surgical setting and applications in oncology.
    Goodnough LT.
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):98-102. PubMed ID: 1928088
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS.
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [Abstract] [Full Text] [Related]

  • 39. Guidelines for recombinant human erythropoietin therapy.
    Eschbach JW, Adamson JW.
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):2-8. PubMed ID: 2667349
    [Abstract] [Full Text] [Related]

  • 40. Practical considerations of recombinant human erythropoietin therapy.
    Paganini EP, Latham D, Abdulhadi M.
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):19-25. PubMed ID: 2667348
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.